IndustryCompany release

Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow

🇺🇸 Aytu Biopharma, Inc (AYTU) · Mon 16 Nov 2026

Aytu reported first-quarter FY2027 revenue of $14.8M, with EXXUA contributing $4.9M, and agreed a $2.70-per-share cash tender offer from Rosemont Pharmaceuticals Holdings.

Aytu BioPharma reported results for the quarter ended 30 September 2026 on 16 November, posting net revenue of $14.8M, an increase of 6.9%. The company recorded a net loss of $3.9M for the period.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Aytu Biopharma, Inc ↗

Article written by VigiEye from the official source (Aytu Biopharma, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →